Congratulations to our portfolio company Echo on their acquisition by CELLINK!

Watch our CEO, Neil Littman, share the story that inspired him to found Bioverge.

Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.

Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.

The Bioverge Reg CF Offering is Officially Live 🎊 and Accepting Investments!

Impact investing is both financially and socially rewarding, providing benefits to the individual investor and the world at large.

A brief explanation of the importance of diversification in and the unique characteristics of healthcare venture capital investment.

Angel Investing defined: A basic guide to help individual investors understand this new opportunity.

Even in our modern age of medical miracles, the prognosis and treatments for end-stage organ failure are still woefully inadequate. IVIVA Medical is on course to change all that.